Research Analysts Set Expectations for ABEO FY2026 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at Zacks Research dropped their FY2026 earnings estimates for Abeona Therapeutics in a note issued to investors on Monday, August 17th. Zacks Research analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings per share of ($1.04) for the year, down from their prior estimate of ($0.94). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.90) per share.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.12). The firm had revenue of $11.38 million for the quarter, compared to analyst estimates of $12.24 million.

ABEO has been the topic of several other research reports. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings downgraded Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Abeona Therapeutics has an average rating of “Hold” and an average price target of $19.33.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $6.13 on Thursday. Abeona Therapeutics has a 1-year low of $4.00 and a 1-year high of $7.65. The stock has a market cap of $350.51 million, a PE ratio of -5.62 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.40. The firm has a fifty day moving average price of $6.36 and a 200 day moving average price of $5.60.

Insider Activity

In other Abeona Therapeutics news, SVP Brendan M. O’malley sold 12,050 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $6.96, for a total transaction of $83,868.00. Following the transaction, the senior vice president directly owned 427,953 shares of the company’s stock, valued at approximately $2,978,552.88. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Leila Alland sold 11,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $5.92, for a total transaction of $65,120.00. Following the completion of the transaction, the director owned 162,614 shares in the company, valued at approximately $962,674.88. This represents a 6.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 281,078 shares of company stock worth $1,709,923 over the last 90 days. 7.10% of the stock is owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ABEO. Royal Bank of Canada grew its stake in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 2,155 shares during the last quarter. Legato Capital Management LLC raised its stake in shares of Abeona Therapeutics by 21.0% during the fourth quarter. Legato Capital Management LLC now owns 13,180 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 2,290 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Abeona Therapeutics by 6.2% during the fourth quarter. Deutsche Bank AG now owns 39,368 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 2,303 shares during the last quarter. Rangeley Capital LLC lifted its holdings in shares of Abeona Therapeutics by 4.2% during the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 2,400 shares during the period. Finally, LPL Financial LLC lifted its holdings in shares of Abeona Therapeutics by 5.3% during the fourth quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 3,165 shares during the period. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.